NCT01356173View on ClinicalTrials.gov

Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Non-Hodgkin's Lymphoma, Solid Tumor

Interventions

DRUG

GDC-0349

Oral escalating dose

Trial Locations (2)

85258

Scottsdale

M5G 2M9

Toronto

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY

NCT01356173 - Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter